Vertex, a biotechnology company known for its cystic fibrosis treatments, was hurt by a setback in clinical trials for its new therapeutic, suzetrigine, in the chronic pain setting. The company is ...

Leerink Partners analyst David Risinger has reiterated their bullish stance on VRTX stock, giving a Buy rating yesterday.Invest with ...

I last wrote here several months ago about the sodium channel (NaV1.8) inhibitor VX-548 (now known as suzetrigine), which is ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), with its substantial $114.5 billion market capitalization, continues to dominate the cystic fibrosis (CF) treatment market while advancing a ...

However, Vertex has a big opportunity and has over 50 authorized treatment centers activated. The company expects to share ...

A non-opioid painkiller from Vertex Pharmaceuticals could become a blockbuster, but questions remain on whether it will prove safe and effective for chronic pain.

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its fourth quarter and full year 2024 financial results on Monday, February 10, 2025 after the financial markets close. The company will ...

Vertex Pharmaceuticals Incorporated ... designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced multiple program updates ahead of upcoming investor meetings in January, including the company’s scheduled webcast from the 43rd ...

Vertex, a biotechnology company known for its cystic fibrosis treatments, was hurt by a setback in clinical trials for its new therapeutic, suzetrigine, in the chronic pain setting. The company is ...